CD274 and neoplasm: Real-world analyses confirm that nearly half of advanced NSCLC cases are PD-L1 negative (tumor proportion score <1%), a population with median overall survival (OS) rarely exceeding 12–18 months with contemporary chemoimmunotherapy (5–7).